add Tesla to that list of overpriced, hyped, bandwagon stocks. It was a matter of time before that one came crashing down.
I bought it at $36.50 in late December. Glad I did. Long term hold for me. This one along with XOM that I bought at $86.50, and recently SDRL at $10.05 just last week. :)
I know it hasn't reached $.01 yet. Close. But,...is there any chance at all that this will ever go over $.05? What is the possibility that they get bought out? I think they are competing in the same space as Solar City so I am wondering what their chances are to do really well in this part of the industry.
Over $72 today. Yep. stocks looking pretty bad. heh. ;) Still up $50/share from when I bought it!! :)
Pfizer-Fueled Gains on the Horizon
From a financial newsletter:
On the plus side, Opko boasts very low debt and a current ratio of 2.12, which shows that the company has the ability to meet its short-term liquidity needs.
But here’s a bigger reason why investors should remain bullish…
Opko and Pfizer recently announced that they’ve entered into a global agreement for the development and commercialization of Opko’s long-acting hGH-CTP therapy for the treatment of growth hormone deficiency. The treatment primarily targets growth failure in children who do not show catch-up growth by two years of age.
According to the agreement, Opko will receive an upfront payment of $295 million and is eligible to receive an additional $275 million upon the achievement of specific milestones.
In return, Pfizer will receive exclusive licensing rights for the commercialization of hGH-CTP worldwide.
The benefit for Opko shareholders here is obvious: By luring Pfizer’s expertise in realizing the vast potential for hGH-CTP, the alliance could transform Opko’s fortunes and ignite the shares.
Especially since the market value for the therapy is over $3 billion.
You see, hGH-CTP has the potential to be the best-in-class, long-acting growth hormone on the market, and should be immediately accretive to Opko’s bottom line.
Additionally, the Pfizer partnership will reduce the regulatory burden on Opko, as the companies will share the financial responsibility for further global trials.
The company that produces human growth hormones could produce significant wealth growth for shareholders, too. And Opko just put itself in a very strong position.
It's always been a bad idea to short this stock. I can't feel badly for shorts.
personally, I couldn't short a company that is out to help people's health anyway, but shorting a company that Frost is involved in is just bad. ;)
Yep. Got them all on Ignore. Very few posts to look at now. ;)
I'm in for the long haul so if it goes to the $5 range I'll just buy more. Plenty of time to make cash on this.
Probably not soon, but it will get there. Once they open their new factory in 2016 things will happen, but you can't wait until then to get into it.
I am just watching atm.